Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Quetiapine: Pipeline™ Selector' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Quetiapine Pipeline Developer |
Ongoing | £2925 | 100 % |
|
Quetiapine: Core Country Coverage Pipeline Selector |
Ongoing | £260 | 96 % |
|
Quetiapine: Extended Country Coverage Pipeline Selector |
Ongoing | £610 | 96 % |
|
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth |
September 2006 | £6495 | 50 % |
|
Schizophrenia in Focus |
August 2006 | £29.95 | 35 % |
|
Commercial Insight: Depression Atypical lifecycle management strategy rejuvenates depression market |
June 2007 | £7600 | 34.5 % |
|
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
June 2007 | £995 | 33.25 % |
|
Astellas Pipeline Products Performance Potential |
June 2008 | £595 | 24.5 % |
|
Pipeline Insight: Anxiety Disorders A decade of declining revenues |
March 2006 | £6495 | 20.3 % |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £6000 | 19.6 % |
|
Teva Generics Company Intelligence Report Company Intelligence Report |
March 2009 | £195 | 18.9 % |
|
Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value |
October 2008 | £8000 | 17.5 % |
|
Pipeline Insight: Schizophrenia |
July 2006 | £6330 | 14.7 % |
|
Teva Pharmaceutical Industries Generics Company Intelligence Report |
June 2008 | £195 | 13.3 % |
|
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies |
November 2008 | £8000 | 12.25 % |
|
Stakeholder Opinions: Parkinson's Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
July 2006 | £2230 | 8.75 % |
|
Generic Competition, 2007–11 The impact of patent expiries on sales of major drugs |
February 2007 | £1375 | 8.4 % |
|
CNS Generic Drugs: Prospects and Opportunities to 2012 |
April 2008 | £995 | 5.95 % |
|
Handbook of Pharmaceutical Manufacturing Formulations - Vol 1 of 6 Compressed Solid Products |
April 2007 | £195 | 5.6 % |
|
World Generic Market Report 2009 |
January 2009 | £595 | 3.15 % |
